Anti-Human S100A4 Recombinant Antibody (TAB-378CT) (CAT#: TAB-378CT)

Figure 1 Antitumor activity of 5C3.

PBS (negative control) or 5C3 (25 mg/kg) was given i.p. three times a week (1010100). At the end of the experiment, mice were sacrificed and tumors were weighted. Graphs of RTV shows the activity of 5C3 compared with the control group. Bars of tumor weight show the mean ± SEM. *p<0.05.

Hernandez, J. L., Padilla, L., Dakhel, S., Coll, T., Hervas, R., Adan, J., ... & Rodríguez, L. (2013). Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PloS one, 8(9), e72480.

Figure 2 Immunohistologic analysis of tumor microvasculature from MiaPACA-2 tumors in animals treated with 5C3.

Quantifications were made from more than 10 pictures per slice at a magnification of X120 (2.4 mm²). Graphs show the mean ± SEM. *p<0.05.

Hernandez, J. L., Padilla, L., Dakhel, S., Coll, T., Hervas, R., Adan, J., ... & Rodríguez, L. (2013). Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PloS one, 8(9), e72480.

Figure 3 5C3 (1-2 mM) neutralized the production of active forms of MMP-9 induced by S100A4 (arrowhead).

Each data point was normalized to the positive control of cells incubated with complete medium (left bar) that represents 100% migration. The control is the maximum of the possible migration (migration control). This migration is obtained by incubating HUVEC with basal medium containing 10% FCS plus hydrocortisone, brain bovine extract and hEGF. All the experimental points are referred to this control.

Hernandez, J. L., Padilla, L., Dakhel, S., Coll, T., Hervas, R., Adan, J., ... & Rodríguez, L. (2013). Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PloS one, 8(9), e72480.

Figure 4 Dose-response inhibition of S100A4-RAGE interaction by 5C3 mAb.

Antibody was used at 60–500 nM for 2 mM S100A4.

Hernandez, J. L., Padilla, L., Dakhel, S., Coll, T., Hervas, R., Adan, J., ... & Rodríguez, L. (2013). Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PloS one, 8(9), e72480.

Figure 1 Mouse Anti-Human S100A4 Antibody (TAB-378CT) in WB

Western blot analysis of TAB-378CT was performed by loading Recombinant Human Protein S100A4 (expressed in E. coli).

TAB-378CT-L incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Mouse IgG (H+L)
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 2: Reducing Antigen (0.6 μg)

Figure 2 Mouse Anti-Human S100A4 Antibody (TAB-378CT) in ELISA

ELISA analysis of TAB-378CT was performed by coating with Recombinant Human Protein S100A4 (expressed in E. coli).

The secondary antibody: HRP-Anti-Mouse IgG (H+L)

Figure 3 Mouse Anti-Human S100A4 Antibody (TAB-378CT) in Dot Blot

Dot Blot analysis of TAB-378CT was performed by coating with Recombinant Human Protein S100A4 (expressed in E. coli).

TAB-378CT-L incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Mouse IgG (H+L)